Printer Friendly

Immune Response announces United States patent for membrane-bound cytokine compositions.

The Immune Response Corporation (Carlsbad, CA; 760-431-7080) announced it has received a United States patent for Membrane-Bound Cytokine Compositions Comprising GM-CSF and Methods of Modulating an Immune Response Using Same. This patent, number 5,891,432, covers the use of granulocyte-macrophage colony stimulating factor expressed in membrane-bound form to induce a powerful anti-tumor immune response. This proprietary technology combines a tumor cell with the cytokine on its surface as a vaccine designed to stimulate the immune system to destroy the cancer.

"The immune-activating cytokine is bound to the membrane of the tumor cell instead of dissipating into the body, as in existing vaccines, and is therefore able to send a more powerful activation signal to the immune system to recognize and fight cancer cells," according to Dennis J. Carlo, PhD, president and chief executive officer. "This process creates a potentially more effective, genetically altered tumor cell vaccine than is currently available, and in preclinical models, we have protected 100% of the mice from a tumor challenge using this proprietary membrane-bound technology."

Details of these findings have been accepted for publication in the Journal of Immunology.

Immune Response develops immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases, and cancer. The company is conducting clinical trials on immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for melanoma and prostate cancers. In addition, the company is developing a delivery technology to enable intravenously-injected genes to target the liver. This gene therapy program includes preclinical studies for the treatment of hemophilia and hepatitis.
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technology Information
Comment:Immune Response announces United States patent for membrane-bound cytokine compositions.(Technology Information)
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Apr 1, 1999
Previous Article:Use of modern proteomics to discover protein biomarkers of disease.
Next Article:Osteotech announces development in lawsuit against GenSci.

Related Articles
Anergen awarded fundamental patent for technology for autoimmune disease treatment
Corixa receives United States patents on vaccine adjuvant, LeIF.
Altarex licenses United States issued patents for autoimmune disease therapy.
Mojave Therapeutics granted United States patent for DNA based antigen.
Mymetics patents HIV treatment involving retrovirus immune response.
Vical announces issuance of European patents covering platform technology.
Peregrine obtains tumor treatment patent.
Nventa granted European patent covering heat shock protein fusion to treat influenza.
BASF obtains United States patent.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters